NASDAQ:GWPHGW Pharmaceuticals PLC- Stock Price, Forecast & News

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GWPH stock has increased by 46.1% and is now trading at $126.92. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.88) by $0.64. The biopharmaceutical company earned $120.60 million during the quarter, compared to analyst estimates of $84.93 million. GW Pharmaceuticals PLC- had a net margin of 8.42% and a negative return on equity of 9.87%. GW Pharmaceuticals PLC-'s revenue was up 207.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. View GW Pharmaceuticals PLC-'s earnings history.

11 equities research analysts have issued twelve-month price objectives for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $128.00 to $260.00. On average, they anticipate GW Pharmaceuticals PLC-'s share price to reach $187.00 in the next year. This suggests a possible upside of 47.3% from the stock's current price. View analysts' price targets for GW Pharmaceuticals PLC-.

News coverage about GWPH stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a news impact score of 1.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutGW Pharmaceuticals PLC-.

Some companies that are related to GW Pharmaceuticals PLC- include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA), Walt Disney (DIS), Aurora Cannabis (ACB), Intel (INTC) and Gilead Sciences (GILD).

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC-'s stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.99%), Franklin Resources Inc. (7.67%), Janus Henderson Group PLC (5.56%), Canada Pension Plan Investment Board (4.85%), Capital World Investors (3.69%) and M&G Investment Management Ltd. (2.62%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View institutional ownership trends for GW Pharmaceuticals PLC-.

GWPH stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Victory Capital Management Inc., Victory Capital Management Inc., Alliancebernstein L.P., Pictet Asset Management Ltd., Morgan Stanley, M&G Investment Management Ltd., and Deutsche Bank AG. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello, and William A Waldegrave. View insider buying and selling activity for GW Pharmaceuticals PLC-.

GWPH stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Federated Hermes Inc., Canada Pension Plan Investment Board, Loomis Sayles & Co. L P, BlackRock Inc., Capital Research Global Investors, Franklin Resources Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for GW Pharmaceuticals PLC-.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $126.92.

GW Pharmaceuticals PLC- has a market capitalization of $3.92 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.

The official website for GW Pharmaceuticals PLC- is www.gwpharm.com.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]